RASSF10 and exocrine pancreatic carcinoma: In previous studies, we have shown that the RASSF10 promoter is methylated in patient tumors samples of the adrenal gland [24], head and neck [20], sarcoma [20], pancreas carcinoma [20], and Merkel cell carcinoma [25].